0A9G.LSE Mereo BioPharma Group PLC ADR

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0A9G.LSE undervalued?

Graham number

The Graham number of Mereo BioPharma Group PLC ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mereo BioPharma Group PLC ADR fundamental analysis

No fundamental analysis for Mereo BioPharma Group PLC ADR yet.

Mereo BioPharma Group PLC ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mereo BioPharma Group PLC ADR

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autos…

Full company profile